About Low affinity immunoglobulin gamma Fc region receptor III-B
Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B) is a protein
from Homo sapiens identified by UniProt accession
O75015, 233 residues long.
MolForge cross-references it against 0 known binders and
213 disease associations.
Target properties
| Protein name | Low affinity immunoglobulin gamma Fc region receptor III-B |
|---|
| UniProt accession | O75015 |
|---|
| Gene | FCGR3B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 233 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (213)
Diseases linked to this target (Open Targets).
- basophil count · score 0.39
- total blood protein measurement · score 0.37
- monocyte count · score 0.36
- blood protein measurement · score 0.31
- neutrophil count · score 0.30
- serum IgG measurement · score 0.28
- red blood cell density measurement · score 0.27
- basophil percentage of leukocytes · score 0.27
- monocyte percentage of leukocytes · score 0.25
- serum alanine aminotransferase measurement · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75015-F1 | alphafold | PREDICTED | 88.64 | — |
Amino-acid sequence (233 residues)
MWQLLLPTAL LLLVSAGMRT EDLPKAVVFL EPQWYSVLEK DSVTLKCQGA YSPEDNSTQW FHNENLISSQ ASSYFIDAAT VNDSGEYRCQ TNLSTLSDPV QLEVHIGWLL LQAPRWVFKE EDPIHLRCHS WKNTALHKVT YLQNGKDRKY FHHNSDFHIP KATLKDSGSY FCRGLVGSKN VSSETVNITI TQGLAVSTIS SFSPPGYQVS FCLVMVLLFA VDTGLYFSVK TNI
Explore Low affinity immunoglobulin gamma Fc region receptor III-B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets